Products Ofloxacin is commercially available as eye drops, eye ointment (Floxal, Floxal UD), tablets, and solution for injection (Tarivid). The active ingredient was approved in many countries in 1987, and the ophthalmic agents in 1992. The enantiomer levofloxacin is also on the market (Tavanic, generics). This article refers to ocular use. Structure and properties Ofloxacin … Ofloxacin
Products Moxifloxacin is commercially available in the form of film-coated tablets, as an infusion solution, and eye drops (Avalox, Vigamox eye drops). It has been approved in many countries since 1999. Generic versions of the tablets went on sale in 2014. This article refers to oral administration; see also moxifloxacin eye drops. Structure and properties … Moxifloxacin
Products Finafloxacin was approved in the United States in 2015 in the form of ear drops (Xtoro). The drug has not yet been registered in many countries. Structure and properties Finafloxacin (C20H19FN4O4, Mr = 398.4 g/mol) is a fluoroquinolone. It exists as a white to yellow powder or crystals and is sparingly soluble in water. … Finafloxacin
Products Temafloxacin (Omniflox) was withdrawn from the market in 1992 a few months after its initial approval in the United States because of the potential for serious side effects. Structure and properties Temafloxacin (C21H18F3N3O3, Mr = 417.4 g/mol) structurally belongs to the fluoroquinolones. Effects Temafloxacin (ATC J01MA05) is bactericidal. Effects are due to inhibition of … Temafloxacin
Products Ciprofloxacin is commercially available as film-coated tablets, oral suspension, infusion preparation, eye drops, eye ointment (Ciloxan), and ear drops (Ciproxin HC + hydrocortisone). In addition to the original Ciproxin, various generics are available. Ciprofloxacin was approved in many countries in 1987. This article refers to peroral administration. Structure and Properties Ciprofloxacin (C17H18FN3O3, Mr = … Ciprofloxacin
Products Lomefloxacin is included in eye drops in many countries (Okacin). Maxaquin film-coated tablets, approved in 1992, are no longer available (off label). Structure and properties C17H19F2N3O3, Mr = 351.35 g/mol Effects Lomefloxacin (ATC J01MA07) is bactericidal. Indications Bacterial infectious diseases Cf. Quinolones
Products No drugs containing gatifloxacin are registered in many countries. Eye drops are available in the United States. Tablets and solutions for injection are no longer available because of glucose metabolism disorders (dysglycemia: hypoglycemia, hyperglycemia) that occurred with systemic administration. Gatifloxacin was first approved in 1999. Structure and properties Gatifloxacin (C19H22FN3O4, Mr = 375.4 g/mol) … Gatifloxacin
Products Grepafloxacin is no longer commercially available because of potential adverse effects. Raxar or Vaxar film-coated tablets were withdrawn from the market in 1999. Structure and properties Grepafloxacin (C19H22FN3O3, Mr = 359.4 g/mol) is present in drugs as grepafloxacin hydrochloride. Effects Grepafloxacin (ATC J01MA11) has bactericidal properties against Gram-positive and Gram-negative pathogens. The effects are … Grepafloxacin
Products Norfloxacin is commercially available in the form of film-coated tablets. It was approved in many countries in 1983. The original product, Noroxin, is no longer available, but generics are available. Structure and properties Norfloxacin (C16H18FN3O3, 319.33 g/mol) is a fluoroquinolone. It exists as a white to pale yellow, hygroscopic, photosensitive crystalline powder that is … Norfloxacin
Products Levofloxacin is commercially available as film-coated tablets and as an infusion solution (Tavanic, generic). It was approved in many countries in 1998. Generics came on the market in 2011. In 2018, a solution for a nebulizer was registered (Quinsair). The racemate ofloxacin is available as tablets (Tarivid), eye drops, and eye ointment (Floxal). Structure … Levofloxacin
Products Trovafloxacin was commercially available in many countries as film-coated tablets and as an infusion concentrate (Trovan, Pfizer). It was withdrawn from the market in 1999 because of potential adverse effects. Structure and properties Trovafloxacin (C20H15F3N4O3, Mr = 416.4 g/mol) is a fluoronaphthyridone. It is present in tablets as trovafloxacin mesilate. In parenteral dosage forms, … Trovafloxacin
Products Ozenoxacin was approved in the United States in 2017 as a cream (Xepi). Structure and properties Ozenoxacin (C21H21N3O3, Mr = 363.4 g/mol) exists as a white to slightly yellow powder. Unlike most quinolones, it is not fluorinated. Ozenoxacin carries a pyridinyl group at position C-7. Effects Ozenoxacin has bactericidal properties and is effective against … Ozenoxacin
